World's Best Scientists 2026 revealed!
Harold J. Burstein

Harold J. Burstein

D-Index & Metrics

Medicine

D-Index
111
Citations
61500
World Ranking
5249
National Ranking
2832

Overview

Harold J. Burstein is affiliated with Harvard University in the United States and has a research focus primarily within the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their work spans multiple subfields, with significant contributions in Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Genetics, and Pathology and Forensic Medicine.

Their research concentrates on several key topics, which include:

  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics
  • Estrogen and related hormone effects
  • Monoclonal and Polyclonal Antibodies Research

Burstein has published extensively in well-known venues within oncology and cancer research, among them:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • UNC Libraries
  • Breast Cancer Research and Treatment

Collaborations have played a key role in their research output. Frequent co-authors include Eric P. Winer, Sara M. Tolaney, Hope S. Rugo, Nabihah Tayob, and Ann H. Partridge.

Among recent publications authored by Burstein are:

  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021, published in 2021 in Annals of Oncology

Other influential related publications, where Burstein contributed or are relevant to their field, include:

  • Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology, 2020, Journal of the National Comprehensive Cancer Network
  • Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology, 2022, Journal of the National Comprehensive Cancer Network
  • Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2023, Annals of Oncology
  • Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium, 2020, Breast Cancer Research and Treatment

Best Publications

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Clinical practice guidelines in oncology

    William J. Gradishar;Benjamin O. Anderson;Ron Balassanian;Sarah L. Blair

  • American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer

    Gary H. Lyman;Armando E. Giuliano;Mark R. Somerfield;Al B. Benson

  • American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

    Eric P. Winer;Clifford Hudis;Harold J. Burstein;Antonio C. Wolff

  • Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

    William J. Gradishar;Benjamin O. Anderson;Jame Abraham;Rebecca Aft

  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

  • Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

    Gary H. Lyman;Sarah Temin;Stephen B. Edge;Lisa A. Newman

  • American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

    Harold J. Burstein;Ann Alexis Prestrud;Jerome Seidenfeld;Holly Anderson

  • Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

    Kimberly L. Blackwell;Harold J. Burstein;Anna Maria Storniolo;Hope Rugo

  • Ductal Carcinoma in Situ of the Breast

    Harold J. Burstein;Kornelia Polyak;Julia S. Wong;Susan C. Lester

  • Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

    Johanna C. Bendell;Susan M. Domchek;Harold J. Burstein M.D.;Lyndsay Harris

  • American Society of Clinical Oncology Clinical Practice Guideline Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

    Harold J. Burstein;Jennifer J. Griggs;Ann A. Prestrud;Sarah Temin

  • Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

    Harold J. Burstein;Harold J. Burstein;Sarah Temin;Holly Anderson;Thomas A. Buchholz

  • Use of alternative medicine by women with early-stage breast cancer.

    Harold J. Burstein;Shari Gelber;Edward Guadagnoli;Jane C. Weeks

  • Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

    Olivia Pagani;Meredith M. Regan;Barbara A. Walley;Gini F. Fleming

  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

    Sara M. Tolaney;William T. Barry;Chau T. Dang;Denise A. Yardley

  • Adjuvant ovarian suppression in premenopausal breast cancer

    Prudence A. Francis;Prudence A. Francis;Meredith M. Regan;Gini F. Fleming;István Láng

  • Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

    Andrew D. Seidman;Donald Berry;Constance Cirrincione;Lyndsay Harris

  • Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

    Kimberly L. Blackwell;Harold J. Burstein;Anna Maria Storniolo;Hope S. Rugo

  • The distinctive nature of HER2-positive breast cancers.

    Harold J Burstein

Frequent Co-Authors

Eric P. Winer
Eric P. Winer Yale University
Ann H. Partridge
Ann H. Partridge Harvard University
Clifford A. Hudis
Clifford A. Hudis Memorial Sloan Kettering Cancer Center
Antonio C. Wolff
Antonio C. Wolff Johns Hopkins University
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Rebecca Gelman
Rebecca Gelman Harvard University
Lisa A. Carey
Lisa A. Carey University of North Carolina at Chapel Hill
William J. Gradishar
William J. Gradishar Northwestern University
Richard D. Gelber
Richard D. Gelber Harvard University
Meredith M. Regan
Meredith M. Regan Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The field of medicine offers a range of online degrees and career pathways for students seeking flexibility and affordability. Prospective nurses can explore the cheapest bsn to dnp programs to advance into higher clinical or leadership roles while continuing to work.

For those interested in pharmacy, pursuing an online pharmacy degree can open up opportunities in medication management and patient care—without putting a hold on your career or relocation plans.

Not all healthcare careers require direct patient interaction. Earning a bachelor of health information management online is an excellent path for those interested in health data, records management, and technology roles in the medical sector.

Additionally, understanding how much does it cost to become a medical coder can help you estimate your investment when considering in-demand administrative careers that support healthcare delivery.

With diverse flexible options available, these online degrees make healthcare careers more accessible to students across the country.

Best Scientists Citing Harold J. Burstein

Trending Scientists